Ultrastructural localization of adhalin, a-dystroglycan a n d merosin in normal a n d dystrophic muscle Adhalin and a-dystroglycan are two components of a complex of proteins that, in conjunction with dystrophin, provide a link between the subsarcolemmal cytoskeleton and the basal lamina of the extracellular matrix of skeletal muscle. In the absence of dystrophin, in Duchenne muscular dystrophy (DMD) and the mdx mouse, levels of adhalin, a-dystroglycan and other components of the complex, are severely reduced, and it has been speculated that this might be an important factor in precipitating myofibre necrosis. However, there is, as yet, little information on how these proteins interact structurally or functionally. From biochemical data it might be predicted that adhalin and a-dystroglycan are positioned more peripherally in the muscle cell than dystrophin and more proximal than merosin. Using single and double immunogold labelling we here show that adhalin is localized to the plasma membrane with the majority of the gold probe particles situated on the membrane's outer face, while a-dystroglycan labelling is seen on material which projects from the outer face and which, in places, forms strands that stretch to the basal lamina. When double labelling of laminin and a-dystroglycan is carried out, laminin is localized to the proximal face of the basal lamina, facing the a-dystroglycan. In DMD the labelling of adhalin and a-dystroglycan is severely reduced quantitatively (although the vestige that remains is positioned normally) but merosin is expressed normally, showing that its incorporation is independent of that of dystrophin and its associated proteins.
Introduction
Dystrophin, the protein absent in Duchenne muscular dystrophy (DMD), is bound to a large oligomeric complex of proteins localized to the plasma membrane [4, 7. 231. The complex consists of a cytoplasmic protein triplet of 59 kDa (59DAP or syntrophin), a transmembrane protein of 2 5 kDa (2 SDAP), four transmembrane glycoproteins (35DAG, adhalin or 50DAG, and a 4 3 kDa doublet [P-dystroglycan and a novel 43 kDa glycoprotein, 43DAG, also known asA3bI) and a n extracellular glycoprotein of 156 kDa (1 56DAG or a-dystroglycan). Alpha and P-dystroglycan are post-translationally spliced products of a single gene, so named because of their interaction with dystrophin and the heavily glycosylated nature of a-dystroglycan [ l l ] . In contrast to the dystroglycans which are L L J~ specific to muscle, adhalin is expressed only in skeletal, cardiac and smooth muscle. Alpha-dystroglycan binds to merosin (M-laminin or laminin 2) in the basal lamina 19, 11.1 which is a secretion product of the myofibres and part of the extracellular While DMD is caused by an absence of dystrophin, UK. other disorders result from abnormalities of the dystrophin associated proteins. Thus, limb girdle muscuMuscle lar dystrophy type 2C is associated with adhalin deficiency and is linked with an unidentified gene on chromosome 1 3 [3] while limb girdle dystrophy type 2D is associated with mutations in the adhalin gene on chromosome 17 [17] . Adhalin deficiency has also been observed in the hereditary myopathy and cardiomyopathy in the hamster [16] . In Fukuyama-type congenital muscular dystrophy, reduced labelling of P-dystroglycan is seen in some fibres [13] . A proportion of cases of classical congenital muscular dystrophy (CMD) and dyldy mouse dystrophy have recently been associated with a deficit in merosin expression [2, 191 , and linkage analysis has placed the CMD locus near the merosin gene [lo] .
It follows from the above observations that a range of disorders that are genetically distinct but related (in that they all cause muscle necrosis) is produced by changes in components that physically span a very small part of the muscle cell, and it is therefore highly important that the morphological relationship of the different components is clarified. The resolution of immunofluorescence techniques is inadequate for this, so ultrastructural methods have been employed. Immunogold techniques have been applied in several laboratories to the localization of dystrophin [5, 20, 221 and, more recently, to P-dystroglycan [6] . In the present study we have extended this approach to include the ultrastructural localization of adhalin, a-dystroglycan and merosin. We have also carried out double immunogold labelling and shown that the relative disposition of the different components is largely in accord with models based on biochemical studies.
Materials and methods

Antibodies
Monoclonal
(1) Anti-adhalin antibody IVD3, [12] . The muscle samples examined were obtained by open biopsy from the vastus lateralis muscle from patients at the Regional Neurosciences Centre, Newcastle General Hospital. Biopsy samples from six patients with DMD and 10 non-Xp2l dystrophy cases were studied. The ages of the six boys with DMD were 2. 3, 4 (two), 6 and 8 years. The non-Xp2 1 dystrophy cases comprised one McArdle's disease, one motor neuron disease, one polymyositis and seven cases of undiagnosed muscle weakness in which the biopsy was histologically and ultrastructurally normal.
Irnrnunolabelling
Small pieces of vastus lateralis muscle were clamped under slight tension in modified hair grips and fixed for 1 h in 2% paraformaldehyde with 0.001% glutaraldehyde in phosphate buffered saline of composition 0.02 M NaH,P042H,0, 0.08 M Na,HP04, 0.15 M NaCl at pH 7.4. After washing in buffer the muscle was cut into blocks x 1.0 x 0.5 x 0.5 mm and transferred to 2.3 M sucrose (as cryoprotectant) for at least 2 h. The blocks were then mounted on aluminium stubs and plunge frozen in liquid nitrogen. Sections were cut at 1 pm for irnmunofluorescence and at 80 nm for EM immunogold labelling using a Reichert Ultracut E microtome fitted with an FC4D cryomicrotomy attachment (knife temperature -110 "C, block temperature -90 "C). The 1 pm sections were mounted on gelatinized slides, rinsed, blocked with 50 m~ ammonium chloride and rinsed again, after which the primary antibody was applied for I h at room temperature. After thorough washing in buffer the labelling was visualized with rhodamineconjugated rabbit anti-mouse IgG (1: 100; DAKO R2 70). After washing, the sections were mounted in Uvinert before examination using a fluorescence-optics microscope. The 80 nm sections were collected on to formvarl carbon-coated 200-mesh copper grids and placed on to drops of chilled 2% gelatin to stabilize. Three consecutive blocking steps were applied using ammonium chloride, 50 m~ for 1 5 min, glycine, 0.02 M for 15 min and 10% normal goat serum for 30 min. The grids were then floated on drops of primary antibody for 1 h. After washing in buffer the grids were incubated with the gold-conjugated secondary antibody for 1 h at room temperature. After further washing the sections were stabilized in 2% methyl cellulose containing 0.4% uranyl acetate and allowed to air dry. The sections were examined in a JEOL 1200EX electron microscope.
Controls
When labelling with a monoclonal antibody, control sections were incubated, in parallel, with diluted nonimmune mouse serum followed by the appropriate goat anti-mouse gold conjugate. Other control sections were incubated with the buffer alone followed by the gold conjugate. The same controls were carried out when labelling with the polyclonal antibodies except that non-immune rabbit serum was used.
Double labelling
To carry out double labelling, the sections were first labelled by the usual procedure with one of the antibodies (monoclonal or polyclonal) and the appropriate goldconjugate and, after washing, were then labelled with the second antibody (raised in a different species to the first antibody) and a gold-conjugate of a different size to that used for the first antibody. Due to the unavailability of a polyclonal antibody to merosin at the time, double labelling of a-dystroglycan and the basal lamina was carried out using a polyclonal antibody to laminin. (The monoclonal antibody recognizes the a2 chain of laminin while the polyclonal recognizes more than one chain but not the a2. Thus while the epitopes of the two antibodies are different they will label the same molecules.) As a control for the double labelling, the position and density of labelling was compared with that for single labelling with each antibody. In order to control for possible crossreactivity or steric hindrance, the labelling for the two antibodies was also carried out in the reversed sequence.
Results
Control muscle Adhalin
Immunofluorescence labelling of the control muscle showed strong labelling with IVD3, at the periphery of the fibres (Figure la) .
At the ultrastructural level, immunogold labelling was seen mostly close to the plasma membrane and almost entirely on the outer face of it (Figure 2 ). Faint strands of material could often be seen stretched between the basal lamina and plasma membrane, and the adhalin labelling was often seen near the base of these strands (Figure 2 ).
Alpha-dystroglycan
Immunofluorescence labelling of the control muscle showed very intense labelling with 11H6 at the periphery of the fibres (Figure lb) . Where the basal lamina had pulled away from the underlying fibre, probably during sectioning, a low intensity fluorescence was associated with the lamina. Ultrastructurally, immunogold labelling was found on the outer side of the plasma membrane, usually at a site where material that was denser than the background could be seen projecting from the outer face (Figure 3 ). There was frequent multiple labelling by the gold at each site, which we attribute to l l H 6 being an IgM class molecule and therefore, as a pentamer. possessing more antigenic sites for binding by the goldconjugated secondary antibody.
Merosin
By immunofluorescence, anti-merosin clearly defined the periphery of each muscle fibre (Figure 4) . At the ultrastructural level, immunogold labelling was confined to the basal lamina, and within the basal lamina itself labelling was mainly located at the side facing the plasma membrane ( Figure 5 ). In places, strands of material could be detected connecting the basal lamina and plasma membrane and these were often associated with immunogold labelling close to the basal lamina end ( Figure 5 ). Immunogold labelling of larninin was indistinguishable from that of merosin.
Alpha-dystroglycan and dystrophin
When double labelling of a-dystroglycan and dystrophin was carried out, a clear topographical segregation of the two labelling sites could be distinguished. In Figure  6 , for example, the 15 nm immunogold labelling a-dystroglycan is all positioned external to the plasma membrane while the 10 nm gold labelling dystrophin is mostly either on the membrane or immediately internal to it. In places an approximate correspondence can be seen between the labelling sites on either side of the membrane.
Alpha-dystroglycan and laminin
Double labelling was carried out using 5 nm immunogold to localize the a-dystroglycan and 1 0 nm gold to label laminin (Figure 7) . The a-dystroglycan was strongly labelled and in places appeared to be pulled out in strands that cross the gap between the plasma membrane and the basal lamina. a-dystroglycan, as with adhalin, showed a severe reduction in intensity when compared with controls ( Figure  8b ). The remaining labelling, however, was less uniform and more patchy compared with that of adhalin. At the ultrastructural level, immunogold labelling was found in the same position as in controls but at a notably lower density. The merosin labelling of the basal laminae of myofibres in DMD appeared as strong as that in controls by both immunofluorescence and immunogold labelling.
Discussion
The aim of this study was to investigate the normal location of adhalin and a-dystroglycan and to examine to what extent this was altered in dystrophic muscle in which there is an absence of dystrophin. Based on a large amount of biochemical evidence, several schematic models have been proposed for the structure of the dystrophin-glycoprotein complex at the plasma membrane [l, 8, 14, 181. There are a number of specific differences between these models, but certain general features are common to each one. Thus, in each model, extracellular side of the plasma membrane where it binds to merosin located in the basal lamina, and, adhalin, while classified as an integral membrane protein, is Immunofluorescence labelling of merosin and laminin considered to have a large extracellular component.
(not shown) clearly defined the periphery of the muscle (There is biochemical evidence that the adhalin antibody fibres. The immunogold labelling, with localization used in this study, IVD3, recognizes an epitope in this mostly on the side of the basal lamina facing the plasma extracellular region [unpublished data].) The results membrane, is in accord with the schematic models described in this paper give strong morphological (Figure 9 ). The immunogold particles were often situated support to these general models of the dystrophinat the basal lamina ends of pale strands of material that glycoprotein complex. Immunogold labelling of alinked the plasma membrane and the basal lamina dystroglycan shows very clear localization on the ( Figure 5 ). These strands could represent part of protein extracellular side of the plasma membrane (Figure 3) . molecules or carbohydrate moieties involved in connectImmunofluorescence labelling of adhalin appears very ing the two structures. Double labelling experiments, in similar to that of a-dystroglycan and the immunogold which both laminin and a-dystroglycan were labelled, labelling clearly defines an epitope in the extracellular show a-dystroglycan label clustered at the base of domain of the molecule (Figure 2 ). Where double labelthe strands (Figure 7 ) which suggests that they may ling of a-dystroglycan and dystrophin was carried out, represent the carbohydrate component extensions to the gold particles labelling a-dystroglycan were frea-dystroglycan. Moreover adhalin was frequently localquently in the vicinity of gold particles labelling dysized to the base of the strands (Figure 2 ) which further trophin with the a-dystroglycan gold nearly invariably suggests that they mark the position of the glycoprotein external to the plasma membrane and the dystrophin complex. gold internal to it or overlying it. The relative positions of
The dimensions of the gap (sometimes termed the a-dystroglycan and dystrophin were therefore in accord lamina lucida) between the plasma membrane and the with the models depicted in the literature (Figure 9 ). basal lamina, is very variable and partly dependent on the method of preparation of the muscle. We consider that in the present preparations it is exaggerated and that the two layers in vivo are almost certainly more closely adjacent, and the two epitopes labelled, for example in Figure 7 , are more closely positioned than appears in the micrographs. We do not, however, consider that the strands of material connecting the plasma membrane and basal lamina are artefactual as these have been described in muscle prepared in different ways [21] .
Dystrophic muscle
Immunofluorescence (Figure 8 ) and immunogold labelling of both adhalin and a-dystroglycan was considerably reduced in the DMD patients compared with controls. and in relation to this, the loss of which particular component of the DGC initiates cell necrosis in DMD remains to be determined.
